JP2009544618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544618A5 JP2009544618A5 JP2009520862A JP2009520862A JP2009544618A5 JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5 JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aliphatic
- ring
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 Chemical compound CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 0.000 description 73
- YMQLSSLCXRWKQA-UHFFFAOYSA-O CC(C(N1)=O)(NC1=O)[IH+] Chemical compound CC(C(N1)=O)(NC1=O)[IH+] YMQLSSLCXRWKQA-UHFFFAOYSA-O 0.000 description 3
- SWFZYGSTUWMTPI-UHFFFAOYSA-N CC(C)(C=CN1)C1=O Chemical compound CC(C)(C=CN1)C1=O SWFZYGSTUWMTPI-UHFFFAOYSA-N 0.000 description 3
- BTJMCRAWBQGQIK-UHFFFAOYSA-N CC(C)(c(ccnc1)c1N1)C1=O Chemical compound CC(C)(c(ccnc1)c1N1)C1=O BTJMCRAWBQGQIK-UHFFFAOYSA-N 0.000 description 3
- FWWMMGOPZBVMNB-UHFFFAOYSA-N CC(C)(c(nccc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(nccc1)c1N1)/C1=[O]\C FWWMMGOPZBVMNB-UHFFFAOYSA-N 0.000 description 3
- CZGJOXNVXIVFAV-UHFFFAOYSA-N CC(C)(c(ncnc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(ncnc1)c1N1)/C1=[O]\C CZGJOXNVXIVFAV-UHFFFAOYSA-N 0.000 description 3
- OISPDNWOHCABMC-UHFFFAOYSA-N CC(C)C(C)(C1C(N2)OCCC1)C2=O Chemical compound CC(C)C(C)(C1C(N2)OCCC1)C2=O OISPDNWOHCABMC-UHFFFAOYSA-N 0.000 description 3
- SHAYFAIWNAOVSE-UHFFFAOYSA-N CC(C)C(C)(c1c(N2)nc[s]1)C2=O Chemical compound CC(C)C(C)(c1c(N2)nc[s]1)C2=O SHAYFAIWNAOVSE-UHFFFAOYSA-N 0.000 description 3
- QGECDFDEEKEVJO-UHFFFAOYSA-N CC(C)C(C)(c1cccnc1N1)C1=O Chemical compound CC(C)C(C)(c1cccnc1N1)C1=O QGECDFDEEKEVJO-UHFFFAOYSA-N 0.000 description 3
- SXVJIQFQZNOJAX-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[IH]C Chemical compound CC(C)C(CC(N1)=O)(C1=O)[IH]C SXVJIQFQZNOJAX-UHFFFAOYSA-N 0.000 description 3
- WWFBWCVOVMKUCZ-UHFFFAOYSA-O CC(C1=C(N2)OCC1)(C2=O)[IH+] Chemical compound CC(C1=C(N2)OCC1)(C2=O)[IH+] WWFBWCVOVMKUCZ-UHFFFAOYSA-O 0.000 description 3
- FHDPJMNNOTUEKT-UHFFFAOYSA-N CC(C1=C(N2)OCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)OCCC1)(C2=O)[IH]I FHDPJMNNOTUEKT-UHFFFAOYSA-N 0.000 description 3
- LVQDZEAOMZKSMI-UHFFFAOYSA-N CC(C1=C(N2)SCC1)(C2=O)I Chemical compound CC(C1=C(N2)SCC1)(C2=O)I LVQDZEAOMZKSMI-UHFFFAOYSA-N 0.000 description 3
- OYOMJOLPSFPIBL-UHFFFAOYSA-N CC(C1C(N2)SCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)SCC1)(C2=O)[IH]C OYOMJOLPSFPIBL-UHFFFAOYSA-N 0.000 description 3
- DQFMPTUTAAIXAN-UHFFFAOYSA-N CC1(C)N=CNC1=O Chemical compound CC1(C)N=CNC1=O DQFMPTUTAAIXAN-UHFFFAOYSA-N 0.000 description 3
- CEDXQSMKYRXVHU-UHFFFAOYSA-N C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C Chemical compound C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C CEDXQSMKYRXVHU-UHFFFAOYSA-N 0.000 description 3
- DFIMFVQCVXMERG-UHFFFAOYSA-N O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 Chemical compound O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 DFIMFVQCVXMERG-UHFFFAOYSA-N 0.000 description 3
- BDEDPOLWMVWPSK-UHFFFAOYSA-N CC(C)(c1c(N2)nc[nH]1)C2=O Chemical compound CC(C)(c1c(N2)nc[nH]1)C2=O BDEDPOLWMVWPSK-UHFFFAOYSA-N 0.000 description 2
- FRUIAUUIOLTTEA-UHFFFAOYSA-N CC(C)(c1c(N2)nc[o]1)C2=O Chemical compound CC(C)(c1c(N2)nc[o]1)C2=O FRUIAUUIOLTTEA-UHFFFAOYSA-N 0.000 description 2
- FMYHJHHHIIJHRN-UHFFFAOYSA-N CC(C)C(C)(c(nccc1)c1N1)C1=O Chemical compound CC(C)C(C)(c(nccc1)c1N1)C1=O FMYHJHHHIIJHRN-UHFFFAOYSA-N 0.000 description 2
- NSEAPTQEZZLMKF-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[I](C)I Chemical compound CC(C)C(CC(N1)=O)(C1=O)[I](C)I NSEAPTQEZZLMKF-UHFFFAOYSA-N 0.000 description 2
- RNWFHTNSACTMTG-UHFFFAOYSA-N CC(C)C1(C(C)I)N=CNC1=O Chemical compound CC(C)C1(C(C)I)N=CNC1=O RNWFHTNSACTMTG-UHFFFAOYSA-N 0.000 description 2
- CYKTWUBYWZXJSX-UHFFFAOYSA-N CC(C1=C(N2)SCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)SCCC1)(C2=O)[IH]I CYKTWUBYWZXJSX-UHFFFAOYSA-N 0.000 description 2
- VHNASZIROAFYSA-UHFFFAOYSA-O CC(C1C(N2)OCC1)(C2=O)[IH+](C)C Chemical compound CC(C1C(N2)OCC1)(C2=O)[IH+](C)C VHNASZIROAFYSA-UHFFFAOYSA-O 0.000 description 2
- LBHWSNRLSIZGPI-UHFFFAOYSA-N CC(C1C(N2)OCCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)OCCC1)(C2=O)[IH]C LBHWSNRLSIZGPI-UHFFFAOYSA-N 0.000 description 2
- VFJSJACITUAVID-UHFFFAOYSA-N CC(C=CN1)(C1=O)[IH]I Chemical compound CC(C=CN1)(C1=O)[IH]I VFJSJACITUAVID-UHFFFAOYSA-N 0.000 description 2
- IJUNQHFGBLBXBB-UHFFFAOYSA-N CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C Chemical compound CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C IJUNQHFGBLBXBB-UHFFFAOYSA-N 0.000 description 2
- BNMHGYUQURKKHB-UHFFFAOYSA-N C[IH]C1=[O][IH]c(ccnc2)c2N1 Chemical compound C[IH]C1=[O][IH]c(ccnc2)c2N1 BNMHGYUQURKKHB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83239706P | 2006-07-21 | 2006-07-21 | |
| US60/832,397 | 2006-07-21 | ||
| PCT/US2007/016559 WO2008011190A1 (en) | 2006-07-21 | 2007-07-23 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544618A JP2009544618A (ja) | 2009-12-17 |
| JP2009544618A5 true JP2009544618A5 (https=) | 2011-08-18 |
| JP5511379B2 JP5511379B2 (ja) | 2014-06-04 |
Family
ID=38754729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520862A Expired - Fee Related JP5511379B2 (ja) | 2006-07-21 | 2007-07-23 | Ｃｇｒｐレセプターアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7842686B2 (https=) |
| EP (1) | EP2049532B1 (https=) |
| JP (1) | JP5511379B2 (https=) |
| CN (1) | CN101516875A (https=) |
| AT (1) | ATE469895T1 (https=) |
| AU (1) | AU2007275577A1 (https=) |
| CA (1) | CA2658573A1 (https=) |
| DE (1) | DE602007006961D1 (https=) |
| ES (1) | ES2343481T3 (https=) |
| WO (1) | WO2008011190A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3069731A1 (en) | 2005-11-14 | 2016-09-21 | Labrys Biologics Inc. | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| AU2007284994B2 (en) | 2006-05-09 | 2010-04-22 | Merck Sharp & Dohme Corp. | Substituted spirocyclic CGRP receptor antagonists |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| DK2227257T3 (da) | 2008-01-07 | 2013-09-30 | Salutaris Medical Devices Inc | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| WO2009109908A1 (en) | 2008-03-04 | 2009-09-11 | Pfizer Limited | Methods of treating inflammatory pain |
| RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
| US8765759B2 (en) * | 2008-03-28 | 2014-07-01 | Merck Sharp & Dohme Corp. | Monocyclic CGRP receptor antagonists |
| CA2735821A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide cgrp receptor antagonists |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| CN102740884A (zh) | 2009-08-28 | 2012-10-17 | 瑞纳神经科学公司 | 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法 |
| PE20141787A1 (es) | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| TWI705825B (zh) | 2011-05-20 | 2020-10-01 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）或抗降血鈣素基因相關胜肽受器（ａｎｔｉ－ｃｇｒｐ－ｒ）抗體或抗體片段治療或預防慢性及急性型腹瀉之用途 |
| CN107827982B (zh) | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| TWI646099B (zh) * | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| CN109952314A (zh) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| JP7208137B2 (ja) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| CA3077973A1 (en) | 2020-04-06 | 2021-10-06 | H. Lundbeck A/S | Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies |
| TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
| CN118541030A (zh) * | 2022-01-14 | 2024-08-23 | 恩科化学公司 | 原卟啉原氧化酶抑制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004222328B2 (en) * | 2003-03-14 | 2009-10-08 | Merck Sharp & Dohme Corp. | Aryl spirohydantoin CGRP receptor antagonists |
| ATE394400T1 (de) * | 2003-03-14 | 2008-05-15 | Merck & Co Inc | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten |
| CA2519515A1 (en) * | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| EP1606264B1 (en) * | 2003-03-14 | 2012-05-02 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin cgrp receptor antagonists |
| AU2004222378B2 (en) * | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| US7750010B2 (en) * | 2004-09-13 | 2010-07-06 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantion CGRP receptor antagonists |
| US7659264B2 (en) * | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
-
2007
- 2007-07-23 DE DE602007006961T patent/DE602007006961D1/de active Active
- 2007-07-23 WO PCT/US2007/016559 patent/WO2008011190A1/en not_active Ceased
- 2007-07-23 JP JP2009520862A patent/JP5511379B2/ja not_active Expired - Fee Related
- 2007-07-23 AT AT07796984T patent/ATE469895T1/de not_active IP Right Cessation
- 2007-07-23 CN CNA2007800342187A patent/CN101516875A/zh active Pending
- 2007-07-23 CA CA002658573A patent/CA2658573A1/en not_active Abandoned
- 2007-07-23 AU AU2007275577A patent/AU2007275577A1/en not_active Abandoned
- 2007-07-23 EP EP07796984A patent/EP2049532B1/en not_active Not-in-force
- 2007-07-23 ES ES07796984T patent/ES2343481T3/es active Active
-
2009
- 2009-01-21 US US12/356,745 patent/US7842686B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544618A5 (https=) | ||
| JP7664947B2 (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP7846132B2 (ja) | Ｎａｖ１．８阻害薬としてのアリール ３－オキソピペラジンカルボキサミド類及びヘテロアリール ３－オキソピペラジンカルボキサミド類 | |
| CA2915561C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| US20220380338A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JP7331843B2 (ja) | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 | |
| CA3121719A1 (en) | Amino-acid anilides as small molecule modulators of il-17 | |
| JP2016516043A5 (https=) | ||
| JP2011523412A5 (https=) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| CA3075669A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| TW200305425A (en) | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient | |
| JP2012517446A (ja) | Ｓ１ｐ５受容体の作動薬および拮抗薬ならびにそれらの使用方法 | |
| JP7794910B2 (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| UA128085C2 (uk) | ТРЕТИННІ СПИРТИ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| UA128288C2 (uk) | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| CA3173777A1 (en) | Inhibitors and degraders of pip4k protein | |
| JP2017538753A5 (https=) | ||
| CA2948543A1 (en) | Carboxamide derivatives | |
| KR20110044947A (ko) | 과잉활성 면역계 치료를 위한 사이클로리그난의 용도 | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль |